Form 4: Kiromic Biopharma CEO Pietro Bersani Receives Restricted Stock Award
SEC Form 4
Kiromic Biopharma's CEO, Pietro Bersani, was granted a restricted stock award of 45,968 shares on May 3, 2024, vesting on April 1, 2025.
Summary
- Pietro Bersani, CEO of Kiromic Biopharma, received a restricted stock award.
- The transaction occurred on May 3, 2024.
- The award consists of 45,968 shares of Kiromic Biopharma stock.
- The restricted stock vests on April 1, 2025.
- The price of the restricted stock award is $0.00.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard executive compensation practice.
Positives
- The CEO's receipt of a restricted stock award aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
Industry Context
Stock awards to executives are a common practice in the biopharmaceutical industry to incentivize performance and align management's interests with those of shareholders.
Stakeholder Impact
- Shareholders may view the stock award positively as it aligns the CEO's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 05/03/2024 | Date of the restricted stock award transaction. |
| 04/01/2025 | Vesting date of the restricted stock award. |
| 05/07/2024 | Date of signature on the Form 4 filing. |
Keywords
Kiromic Biopharma, Pietro Bersani, restricted stock award, CEO, KRBP, Form 4, beneficial ownership, equity securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.